"Adjunct therapy for treatment of seizures associated with Lennox-Gastaut syndrome. "@en . . "# Arroyo S: Rufinamide. Neurotherapeutics. 2007 Jan;4(1):155-62. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17199032 # Hakimian S, Cheng-Hakimian A, Anderson GD, Miller JW: Rufinamide: a new anti-epileptic medication. Expert Opin Pharmacother. 2007 Aug;8(12):1931-40. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17696794 # Rufinamide: CGP 33101, E 2080, RUF 331, Xilep. Drugs R D. 2005;6(4):249-52. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15991887 # Wier HA, Cerna A, So TY: Rufinamide for pediatric patients with Lennox-Gastaut syndrome: a comprehensive overview. Paediatr Drugs. 2011 Apr 1;13(2):97-106. doi: 10.2165/11586920-000000000-00000. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/21351809"@en . "Rufinamide was evenly distributed between erythrocytes and plasma. The apparent volume of distribution is dependent upon dose and varies with body surface area. The apparent volume of distribution was about 50 L at 3200 mg/day. Volume of distribution is similar between adults and children and is non-linear. "@en . . . "Rufinamide is a triazole derivative antiepileptic that prolongs the inactive state of voltage gated sodium channels thus stabilizing membranes, ultimately blocking the spread of partial seizure activity."@en . . . . . . . . "Rufinamide"@en . . . . . . . . . . . . . . . . . "Humans and other mammals"@en . . "The most commonly observed adverse reactions (\u226510% and greater than placebo) were headache, dizziness, fatigue, somnolence, and nausea. "@en . . . "Xilep "@en . "26.3% - 34.8% with 90% binding to albumin (27%)."@en . . . . . . . "Rufinamide is a triazole derivative and an anticonvulsant medication to treat seizure disorders like Lennox-Gastuat syndrome, a form of childhood epilepsy. Clinical trials suggest its efficacy in the treatment of partial seizures. "@en . . . . "Emanuele ATTOLINO, Lino COLOMBO, Ilaria MORMINO, Pietro ALLEGRINI, \"METHOD FOR THE PREPARATION OF RUFINAMIDE.\" U.S. Patent US20100234616, issued September 16, 2010."@en . . "The oral suspension and tablet are bioequivalent on a mg per mg basis. Rufinamide is well absorbed but the rate is slow and the extent of absorption decreases as dose is increases. Based on urinary excretion, the extent of absorption was at least 85% following oral administration of a single dose of 600 mg rufinamide tablet under fed conditions. Bioavailability= 70%-85% (decreases with increasing doses); Tmax, fed and fasted states= 4-6 hours; Cmax, 10 mg/kg/day= 4.01 \u00B5L/mL; Cmax, 30mg/kg/day= 8.68 \u00B5L/mL; AUC (0h-12h), 10mg/kg/day= 37.8\u00B147 \u00B5g\u00B7h/mL; AUC (0h-12h), 30mg/kg/day= 89.3\u00B159 \u00B5g\u00B7h/mL. "@en . "106308-44-5"@en . . "Banzel"@en . . . "Elimination half-life, healthy subjects and patients with epilepsy = 6-10 hours. "@en . "Food increases plasma concentrations of rufinamide and slightly decreases half-life (by 3%) "@en . . "approved"@en . . "Renally (91%; 66% as CGP 47292, 2% as unchanged drug) and fecally (9%) eliminated. "@en . "RUF 331"@en . . . .